
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other licensed dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Giant Biogene Holding Co., Ltd, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



GIANT BIOGENE HOLDING CO., LTD

巨子生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

**PROPOSED RE-APPOINTMENT OF AUDITOR
PROPOSED RE-ELECTION OF DIRECTORS
PROPOSED GRANT OF GENERAL MANDATES
TO REPURCHASE SHARES AND ISSUE SHARES
PROPOSED DECLARATION AND DISTRIBUTION OF
FINAL DIVIDENDS AND SPECIAL DIVIDENDS
PROPOSED ADOPTION OF THE AMENDED AND
RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
AND
NOTICE OF ANNUAL GENERAL MEETING**

A notice convening the Annual General Meeting of Giant Biogene Holding Co., Ltd to be held at No. 1855, Shanglin Yuan 7th Road, Chang'an District, Xi'an, Shaanxi Province, the PRC on Thursday, 13 June 2024 at 1:30 p.m. is set out in this circular.

Whether or not you are able to attend the Annual General Meeting, to be valid, please complete and sign the enclosed form of proxy for use at the Annual General Meeting in accordance with the instructions printed thereon and return it to the Company's Hong Kong Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for holding the Annual General Meeting or any adjournment thereof (as the case maybe) (for Annual General Meeting, i.e. not later than Tuesday, 11 June 2024 at 1:30 p.m. (Hong Kong time)). Completion and return of the form of proxy will not preclude the Shareholders from attending and voting in person at the Meeting if they so wish, and in such event, the form of proxy previously submitted will be deemed to be revoked.

This circular together with the form of proxy are also published on the websites of Hong Kong Exchanges and Clearing Limited (<http://www.hkexnews.hk>) and the Company (<http://www.xajuzi.com>).

References to time and dates in this circular are to Hong Kong time and dates.

29 April 2024

CONTENTS

	<i>Page</i>
Definitions	1
Letter from the Board	
1. Introduction	3
2. Proposed Re-appointment of Auditor	4
3. Proposed Re-election of Directors	4
4. Proposed Grant of General Mandate to Repurchase Shares	5
5. Proposed Grant of General Mandate to Issue Shares	5
6. Proposed Declaration and Distribution of Final Dividends and Special Dividends	6
7. Proposed Adoption of the Amended and Restated Memorandum and Articles of Association	6
8. Annual General Meeting and Proxy Arrangement	7
9. Responsibility Statement	8
10. Recommendation	8
11. General Information	8
Appendix I – Details of the Directors Proposed to be Re-elected at the Annual General Meeting	9
Appendix II – Explanatory Statement on the Share Repurchase Mandate	13
Appendix III – Proposed Amendments to the Memorandum and Articles of Association	16
Notice of Annual General Meeting	21

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

“Amended and Restated Memorandum and Articles of Association”	the amended and restated memorandum and articles of association of the Company, incorporating and consolidating all proposed amendments to be considered and approved for adoption by way of special resolution at the Annual General Meeting
“Annual General Meeting” or “AGM”	the annual general meeting of the Company to be held at No. 1855, Shanglin Yuan 7th Road, Chang’an District, Xi’an, Shaanxi Province, the PRC on Thursday, 13 June 2024 at 1:30 p.m. to consider and, if appropriate, to approve the resolutions contained in the notice of the meeting which is set out on pages 21 to 25 of this circular, or any adjournment thereof
“Articles”/“Articles of Association”	the articles of the Company currently in force
“Board”	the board of Directors
“Company”	Giant Biogene Holding Co., Ltd (巨子生物控股有限公司), a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange (Stock code: 02367)
“Director(s)”	the director(s) of the Company
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Date”	4 November 2022
“Latest Practicable Date”	22 April 2024, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information for inclusion in this circular
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended from time to time

DEFINITIONS

“Share(s)”	the ordinary share(s) in the issued share capital of the Company with a par value of US\$0.00001 each or, if there has been a subsequent subdivision, consolidation, reclassification or reconstruction of the share capital of the Company, shares forming part of the ordinary equity share capital of the Company
“Share Issue Mandate”	the general mandate proposed to be granted to the Directors to allot, issue or deal with new Shares of up to 20% in aggregate of the total number of issued Shares (excluding treasury shares) of the Company as at the date of passing of the ordinary resolution item 5 contained in the notice of the Annual General Meeting
“Share Repurchase Mandate”	the general mandate proposed to be granted to the Directors to repurchase Shares on the Stock Exchange of up to 10% of the total number of issued Shares (excluding treasury shares) of the Company as at the date of passing of the ordinary resolution item 4 contained in the notice of the Annual General Meeting
“Shareholder(s)”	holder(s) of Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Takeovers Code”	The Code on Takeovers and Mergers approved by the Securities and Futures Commission, as amended from time to time
“treasury shares”	has the meaning ascribed to it under the Listing Rules which will come into effect on 11 June 2024



GIANT BIOGENE HOLDING CO., LTD

巨子生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

Executive Directors:

Mr. Yan Jianya
(Chairman and chief executive officer)
Ms. Ye Juan
Ms. Fang Juan
Ms. Zhang Huijuan
Ms. Yan Yubo

Independent Non-executive Directors:

Mr. Huang Jin
Mr. Shan Wenhua
Ms. Wong Sze Wing

Registered Office:

PO Box 309, Ugland House
Grand Cayman
KY1-1104
Cayman Islands

*Head Office and Principal Place
of Business in China:*

No. 1855, Shanglin Yuan 7th Road
Chang'an District, Xi'an
Shaanxi Province, the PRC

*Principal Place of Business
in Hong Kong:*

5/F, Manulife Place
348 Kwun Tong Road, Kowloon, Hong Kong

29 April 2024

To the Shareholders

Dear Sir or Madam,

**PROPOSED RE-APPOINTMENT OF AUDITOR
PROPOSED RE-ELECTION OF DIRECTORS
PROPOSED GRANT OF GENERAL MANDATES
TO REPURCHASE SHARES AND ISSUE SHARES
PROPOSED DECLARATION AND DISTRIBUTION OF
FINAL DIVIDENDS AND SPECIAL DIVIDENDS
PROPOSED ADOPTION OF THE AMENDED AND
RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
AND
NOTICE OF ANNUAL GENERAL MEETING**

1. INTRODUCTION

The purpose of this circular is to provide the Shareholders with information in respect of certain resolutions to be proposed at the Annual General Meeting to be held on 13 June 2024.

LETTER FROM THE BOARD

2. PROPOSED RE-APPOINTMENT OF AUDITOR

Ernst & Young, which has audited the consolidated financial statements of the Company for the year ended 31 December 2023, will retire as the auditor of the Company at the Annual General Meeting and, being eligible, offer itself for re-appointment.

The Board, upon the recommendation of the audit committee of the Company, proposed to re-appoint Ernst & Young as the auditor of the Company with a term commencing from the date of the conclusion of Annual General Meeting to the date of the conclusion of the 2024 annual general meeting of the Company, and authorize the Board to fix its remuneration.

3. PROPOSED RE-ELECTION OF DIRECTORS

Pursuant to Article 26.3 of the Articles, the Directors may appoint any person to be a Director, either to fill a vacancy or as an additional Director provided that the appointment does not cause the number of Directors to exceed any number fixed by or in accordance with the Articles as the maximum number of Directors. Any Director so appointed shall hold office only until the first annual general meeting of the Company after such Director's appointment and shall then be eligible for re-election at that meeting. In accordance with the Article, Ms. Zhang Huijuan and Ms. Yan Yubo, who were appointed as Directors by the Board of the Company on 3 October 2023, will hold office until the Annual General Meeting. Pursuant to Article 26.4 of the Articles, at every annual general meeting of the Company, one-third of the Directors for the time being (or, if their number is not three or multiple of three, then the number nearest to, but not less than, one-third) shall retire from office by rotation provided that every Director (including those appointed for a specific term) shall be subject to retirement by rotation at least once every three years. In accordance with the Article, Mr. Yan Jianya and Ms. Ye Juan shall retire as Directors at the Annual General Meeting. All the aforesaid Directors are eligible and will offer themselves for re-election at the Annual General Meeting.

Mr. Yan Jianya, Ms. Ye Juan, Ms. Zhang Huijuan and Ms. Yan Yubo have attended all meetings of the Board and the Board committees (which they serve) held during this financial year and up to the Latest Practicable Date. Details of the attendance records have been set out in the 2023 annual report of the Company. Mr. Yan Jianya, Ms. Ye Juan, Ms. Zhang Huijuan and Ms. Yan Yubo have performed their functions and responsibilities through active participation in the affairs of the Board and introducing balanced views as well as knowledge, experience and expertise to the Board.

The nomination committee has reviewed the structure and composition of the Board, the confirmations and disclosures provided by the Directors, the qualifications, skills and experience, time commitment and contribution of the retiring Directors with reference to the review of the nomination principles and criteria as set out in the Company's Board diversity policy and Director nomination policy and the Company's corporate strategy, and the independence of all independent non-executive Directors. Pursuant to the Board diversity policy, selection of Board candidates will be based on a range of diversity perspectives, including but not limited to gender, age, cultural and

LETTER FROM THE BOARD

educational background, industry experience, technical capabilities, professional qualifications and skills, knowledge, length of service and other related factors. The Company will also consider its own business model and special needs. The ultimate selection of Director candidates will be based on expertise of the candidates and contribution that the candidates will bring to the Board. The nomination committee has recommended to the Board on re-election of all the retiring Directors.

Details of the Directors proposed for re-election at the Annual General Meeting are set out in Appendix I to this circular.

4. PROPOSED GRANT OF GENERAL MANDATE TO REPURCHASE SHARES

At the 2022 annual general meeting of the Company held on 13 June 2023, a general mandate was granted to the Directors to repurchase Shares. Such mandate will lapse upon the conclusion of the Annual General Meeting. In order to give the Company the flexibility to repurchase Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the grant of the Share Repurchase Mandate to the Directors to repurchase Shares on the Stock Exchange of up to 10% of the total number of issued Shares (excluding treasury shares) of the Company as at the date of passing of the ordinary resolution item 4 contained in the notice of the Annual General Meeting (on the basis that the issued share capital of the Company remains unchanged as at the date of the Annual General Meeting, being 99,500,000 Shares).

An explanatory statement required by the Listing Rules to be sent to the Shareholders is set out in Appendix II to this circular. This explanatory statement contains information reasonably necessary to enable Shareholders to make an informed decision on voting for or against the grant of the Share Repurchase Mandate.

5. PROPOSED GRANT OF GENERAL MANDATE TO ISSUE SHARES

At the 2022 annual general meeting of the Company held on 13 June 2023, a general mandate was granted to the Directors to issue Shares. Such mandate will lapse upon the conclusion of the Annual General Meeting. In order to give the Company the flexibility to issue Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the grant of the Share Issue Mandate to the Directors to allot, issue or deal with additional Shares of up to 20% in aggregate of the total number of issued Shares (excluding treasury shares) of the Company as at the date of passing of the ordinary resolution item 5 contained in the notice of the Annual General Meeting (on the basis that the issued share capital of the Company remains unchanged as at the date of the Annual General Meeting, being 199,000,000 Shares). An ordinary resolution to extend the Share Issue Mandate by adding the number of Shares repurchased by the Company pursuant to the Share Repurchase Mandate will also be proposed at the Annual General Meeting.

LETTER FROM THE BOARD

6. PROPOSED DECLARATION AND DISTRIBUTION OF FINAL DIVIDENDS AND SPECIAL DIVIDENDS

In accordance with the annual results announcement for the year ended on 31 December 2023 released by the Company on 25 March 2024, the Board proposed to distribute final dividends of RMB0.44 per ordinary share and special dividends of RMB0.45 per ordinary share, which is subject to the approval by Shareholders at the Annual General Meeting. The final dividends will be paid in HK dollars, the exchange rate of which is based on the official exchange rate of HK dollars against Renminbi as announced by the People's Bank of China on the day when the Annual General Meeting is convened.

The final dividends and special dividends are expected to be paid on or before 5 July 2024 to the Shareholders whose names appear on the register of members of the Company at the close of business hours on 21 June 2024 if the dividends are approved by Shareholders at the Annual General Meeting.

The record date for determining the entitlement to the proposed final dividends and the special dividends is 21 June 2024. To determine the Shareholders who are entitled to the proposed final dividends and the special dividends, the register of members of the Company will be closed from 19 June 2024 to 21 June 2024, both days inclusive, during which period no transfer of Shares of the Company will be registered. In order to be qualified for the proposed final dividends and the special dividends, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's Hong Kong Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on 18 June 2024.

7. PROPOSED ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

Reference is made to the announcement of the Company dated 25 March 2024 in relation to, among others, the proposed adoption of the Amended and Restated Memorandum and Articles of Association. In order to (i) update and bring the Memorandum and Articles of Association in line with the relevant amendments to the Listing Rules in respect of the electronic dissemination of corporate communications by listed issuers (effective from 31 December 2023), and (ii) make other consequential and housekeeping amendments to better align with the wordings and requirements under the applicable laws of the Cayman Islands and the Listing Rules, the Board has passed a resolution on 25 March 2024, proposing to seek approval from the Shareholders by way of special resolution at the Annual General Meeting to amend the Memorandum and Articles of Association by deletion in their entirety and the substitution in their place of the Memorandum and Articles of Association with the Amended and Restated Memorandum and Articles of Association. The adoption of the Amended and Restated Memorandum and Articles of Association is subject to the approval by the shareholders of the Company by way of special resolution at the Annual General Meeting.

LETTER FROM THE BOARD

Details of the proposed amendments brought about by the adoption of the Amended and Restated Memorandum and Articles of Association are set out in Appendix III to this circular. The Amended and Restated Memorandum and Articles of Association are written in English and there is no official Chinese translation in respect thereof. Therefore, the Chinese version of the Amended and Restated Memorandum and Articles of Association is unofficial and for reference only. In case of any discrepancy, the English version shall prevail.

The Company has obtained advice from its legal advisers that the proposed amendments comply with the requirements under the Listing Rules and applicable laws of Cayman Islands. The Company confirmed that there is nothing unusual about the proposed amendments for a company listed on the Stock Exchange.

8. ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT

The notice of the Annual General Meeting is set out on pages 21 to 25 of this circular.

Pursuant to the Listing Rules and the Articles of the Company, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands in accordance with the Listing Rules. An announcement on the poll results will be published by the Company after the Annual General Meeting in the manner prescribed under the Listing Rules.

For determining the entitlement to attend and vote at the Annual General Meeting, the register of members of the Company will be closed from Friday, 7 June 2024 to Thursday, 13 June 2024, both days inclusive, during which period no transfer of Shares will be registered. In order to be eligible to attend and vote at the Annual General Meeting, Shareholders of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's Hong Kong Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Thursday, 6 June 2024.

A form of proxy for use at the Annual General Meeting is enclosed with this circular and such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (<http://www.hkexnews.hk>) and the Company (<http://www.xajuzi.com>). To be valid, the form of proxy must be completed and signed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power of attorney or authority as soon as possible but in any event not less than 48 hours before the time appointed for the Annual General Meeting or any adjournment thereof (as the case may be) (for Annual General Meeting, i.e. not later than Tuesday, 11 June 2024 at 1:30 p.m. (Hong Kong time)). Completion and return of the form of proxy will not preclude you from attending and voting at the Annual General Meeting in person, and in such case, the form of proxy previously submitted shall be deemed to be revoked.

LETTER FROM THE BOARD

9. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

10. RECOMMENDATION

The Directors are of the opinion that the proposed re-election of retiring Directors, the grant of the Share Repurchase Mandate, the grant of the Share Issue Mandate, declaration and distribution of final dividends and special dividends, and adoption of the Amended and Restated Memorandum and Articles of Association are in the best interests of the Company and its Shareholders. Accordingly, the Directors recommend the Shareholders to vote in favor of such resolutions to be proposed at the Annual General Meeting.

11. GENERAL INFORMATION

Your attention is also drawn to the additional information set out in the appendices of this circular. The English text of this circular shall prevail over its respective Chinese text for the purpose of interpretation.

By order of the Board
Giant Biogene Holding Co., Ltd
Yan Jianya
Chairman of the Board

APPENDIX I DETAILS OF THE DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING

The following are details of the Directors who will retire and being eligible, offer themselves for re-election at the Annual General Meeting.

(1) Mr. Yan Jianya

Mr. Yan Jianya, aged 57, was appointed as a Director of the Company on 30 November 2021 and is currently an executive Director, the chairman of the Board, the chief executive officer, chairman of both the nomination committee and corporate governance committee and a member of the remuneration committee of the Company. Mr. Yan founded the Group in May 2000. He is a director and general manager of certain operating subsidiaries of the Group, including Xi'an Giant Biogene and Shaanxi Giant Biotechnology. In 2002, Mr. Yan founded Xi'an Weili Communication Co., Ltd. (西安威力通信有限責任公司) (the predecessor of Xi'an Triangle Defense Incorporated Company (西安三角防務股份有限公司) (a company listed on the ChiNext Market of Shenzhen Stock Exchange, stock code: 300775) ("Triangle Defense")) and has been serving as the chairman of the board of Triangle Defense since September 2015. He served as a director of Xi'an Libang Clinical Nutrition Corporation., Ltd. (西安力邦臨床營養股份有限公司) (a company listed on the National Equities Exchange and Quotations, stock code: 835791) from August 2019 to March 2020. Mr. Yan obtained a bachelor's degree in chemical engineering from Northwest University (西北大學) in the PRC in July 1988.

Mr. Yan Jianya is (i) the spouse of Dr. Fan Daidi, the controlling Shareholder of the Company, (ii) the father of Ms. Yan Yubo, an executive Director, a joint company secretary, the Board secretary and the chief product officer of the Company, and (iii) the brother of Ms. Yan Yajuan, a senior vice president of the Company.

Mr. Yan Jianya is the spouse of Dr. Fan Daidi, the controlling Shareholder of the Company. As such, he is deemed to be interested in the 582,004,935 Shares in the Company held by Dr. Fan. According to the RSU Scheme adopted by the Company on 8 December 2021, Mr. Yan Jianya is entitled to RSUs equivalent to 7,346,037 Shares (subject to vesting conditions), which are held under a trust pursuant to the RSU Scheme.

Mr. Yan Jianya has entered into a service contract with the Company for a term of three years commencing from 30 November 2021 or until the third annual general meeting of the Company from the Listing Date, whichever is earlier, subject always to re-election in accordance with the Articles of Association. Mr. Yan Jianya does not receive Director's fee, but receives a remuneration in accordance with his managerial position of the Company. For the year ended 31 December 2023, Mr. Yan Jianya received a remuneration of RMB698,022 and certain share-based payment, which was borne by the Group and covered by his service contract. The remuneration of Mr. Yan Jianya is determined based on the factors such as market conditions, the Company's performance and his performance assessment results by the Board.

**APPENDIX I DETAILS OF THE DIRECTORS PROPOSED TO BE
RE-ELECTED AT THE ANNUAL GENERAL MEETING**

(2) Ms. Ye Juan

Ms. Ye Juan, aged 53, was appointed as a Director of the Company since 30 November 2021, and is currently an executive Director and a senior vice president of our Company. Ms. Ye has around 20 years of experience in the biotechnology and technical engineering industries. Prior to joining our Group, Ms. Ye worked in the risk management department in China Construction Bank Corporation (a company listed on the Shanghai Stock Exchange (stock code: 601939) and the Hong Kong Stock Exchange (stock code: 939)) from July 1993 to May 2003. She then served as a deputy general manager and subsequently a board secretary in Xi'an Starwave (USA) Communication Equipment Co., Ltd. (西安達威(美國)通信設備有限公司) from July 2003 to February 2010. She then served as a board secretary in Well Logging Energy Technology Xi'an Co., Ltd. (西安威爾羅根能源科技有限公司) from April 2010 to December 2015. She joined our Group in April 2016 as a deputy general manager of Xi'an Giant Biogene and has served as its director since May 2020. Ms. Ye obtained a bachelor's degree in law from Northwestern Polytechnical University (西北工業大學) in the PRC in July 2002.

According to the RSU Scheme adopted by the Company on 8 December 2021, Ms. Ye Juan is entitled to RSUs equivalent to 449,800 Shares (subject to vesting conditions), which are held under a trust pursuant to the RSU Scheme. On 28 December 2023, Ms. Ye Juan was granted 600,000 Share Options under the Share Option Scheme of the Company adopted on 17 August 2023 (subject to vesting conditions).

Ms. Ye Juan has entered into a service contract with the Company for a term of three years commencing from 30 November 2021 or until the third annual general meeting of the Company from the Listing Date, whichever is earlier, subject always to re-election in accordance with the Articles of Association. Ms. Ye Juan does not receive Director's fee, but receives a remuneration in accordance with her managerial position of the Company. For the year ended 31 December 2023, Ms. Ye Juan received a remuneration of RMB882,262 and certain share-based payment, which was borne by the Group and covered by her service contract. The remuneration of Ms. Ye Juan is determined based on the factors such as market conditions, the Company's performance and her performance assessment results by the Board.

**APPENDIX I DETAILS OF THE DIRECTORS PROPOSED TO BE
RE-ELECTED AT THE ANNUAL GENERAL MEETING**

(3) Ms. Zhang Huijuan

Ms. Zhang Huijuan, aged 37, was appointed as a Director of the Company since 3 October 2023, and is currently an executive Director and the chief financial officer of our Company. Ms. Zhang has approximately 15 years of experience in accounting and financial management. Prior to joining the Group, she was a senior auditor in Tianjin Branch of Deloitte Touche Tohmatsu Certified Public Accountants LLP (德勤華永會計師事務所(特殊普通合夥)) from July 2008 to December 2010. She then joined Xi'an Branch of PricewaterhouseCoopers Zhong Tian LLP (普華永道中天會計師事務所(特殊普通合夥)) as an audit manager from January 2011 to September 2018. She served as the director of financial department at Easy Click Worldwide Network Technology Co., Ltd. (易點天下網絡科技股份有限公司) from April 2019 to January 2022. Ms. Zhang obtained the certificate of certified public accountant from the PRC Ministry of Finance in December 2017, the certificate of certified internal auditor from the Institute of Internal Auditors in March 2015, and the certificate of intermediate accountant from the PRC Ministry of Human Resources and Social Security and the PRC Ministry of Finance in October 2013. Ms. Zhang obtained a bachelor's degree in Japanese (international business) from Tianjin Foreign Studies University (天津外國語大學) in July 2008.

According to the RSU Scheme adopted by the Company on 8 December 2021, Ms. Zhang Huijuan is entitled to RSUs equivalent to 640,000 Shares (subject to vesting conditions), which are held under a trust pursuant to the RSU Scheme. On 28 December 2023, Ms. Zhang Huijuan was granted 600,000 options under the share option scheme of the Company adopted on 17 August 2023 (subject to vesting conditions).

Ms. Zhang Huijuan has entered into a service contract with the Company for a term of three years commencing from 3 October 2023, subject always to re-election in accordance with the Articles of Association. Ms. Zhang Huijuan does not receive Director's fee, but receives a remuneration in accordance with her managerial position of the Company. For the year ended 31 December 2023, Ms. Zhang Huijuan received a remuneration of RMB879,112 and certain share-based payment, which was borne by the Group and covered by her service contract. The remuneration of Ms. Zhang Huijuan is determined based on the factors such as market conditions, the Company's performance and her performance assessment results by the Board.

**APPENDIX I DETAILS OF THE DIRECTORS PROPOSED TO BE
RE-ELECTED AT THE ANNUAL GENERAL MEETING**

(4) Ms. Yan Yubo

Ms. Yan Yubo, aged 28, was appointed as a Director of the Company since 3 October 2023, and is currently an executive Director and a joint company secretary and the Board secretary and the chief product officer of the Company. Ms. Yan joined Xi'an Giant Biogene Technology Co., Ltd. in October 2018 as the board secretary and has been responsible for the affairs related to the Group's financing, investor relationship management and corporate governance since then. Ms. Yan obtained the certificate of Financial Risk Manager (FRM) from the Global Association of Risk Professionals in March 2021, the securities qualification certificate from the Securities Association of China in April 2021, the certificate of board secretary from Shanghai Stock Exchange in September 2020, the certificate of board secretary from Shenzhen Stock Exchange in July 2020, and the qualification certificate of fund practitioner from the Asset Management Association of China in November 2019. Ms. Yan obtained a bachelor's degree from the University of Toronto in Canada in June 2017, double majoring in financial economics and statistics, and obtained a master's degree in applied economics from the University of California, Los Angeles in the United States in June 2018.

Ms. Yan Yubo is (i) the daughter of Mr. Yan Jianya, the chairman of the Board, an executive Director and the chief executive officer, and Dr. Fan Daidi, the controlling Shareholder; and (ii) a niece of Ms. Yan Yajuan, a senior vice president of the Company.

Ms. Yan Yubo has entered into a service contract with the Company for a term of three years commencing from 3 October 2023, subject always to re-election in accordance with the Articles of Association. Ms. Yan Yubo does not receive Director's fee, but receives a remuneration in accordance with her managerial position of the Company. For the year ended 31 December 2023, Ms. Yan Yubo received a remuneration of RMB140,570, which was borne by the Group and covered by her service contract. The remuneration of Ms. Yan Yubo is determined based on the factors such as market conditions, the Company's performance and her performance assessment results by the Board.

Save as disclosed above, as of the Latest Practicable Date, the above candidates for re-election of Directors do not have other major appointments and professional qualifications, nor do any of them hold any positions within the Company or its subsidiaries or any directorship in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the past three years prior to the Latest Practicable Date. Meanwhile, none of them have any relationship with any Directors, senior management of the Company, substantial Shareholders or controlling Shareholders of the Company. As at the Latest Practicable Date, save as disclosed above, to the best of the knowledge and belief of the Directors, the above candidates for re-election of Directors do not have any interests in the securities of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). The above candidates for re-election of Directors confirm that there is no any other matter relating to his/her proposed appointment that needs to be brought to the attention of the Shareholders, nor is there any other information that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

The following is an explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on voting for or against the ordinary resolutions to be proposed at the AGM in relation to the Share Repurchase Mandate.

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company was 995,000,000 Shares.

Subject to the passing of the ordinary resolution item 4 contained in the notice of the AGM in respect of the grant of the Share Repurchase Mandate and on the basis that the issued share capital of the Company remains unchanged as at the date of the AGM, being 995,000,000 Shares, the Directors shall be authorized to repurchase up to 99,500,000 Shares, representing 10% of the total issued Shares (excluding treasury shares) as at the date of the AGM, pursuant to the Share Repurchase Mandate during the period in which the Share Repurchase Mandate is in effect.

2. REASONS FOR SHARE REPURCHASE

The Directors believe that the grant of the Share Repurchase Mandate is in the best interests of the Company and its Shareholders.

Repurchase of Shares may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made when the Board believes that such a repurchase will benefit the Company and its Shareholders.

3. FUNDING OF SHARE REPURCHASE

The Company may only apply funds legally available for share repurchase in accordance with its Articles, the laws of the Cayman Islands and/or any other applicable laws, as the case may be.

4. IMPACT OF SHARE REPURCHASE

There might be an adverse impact on the working capital or gearing position of the Company (as compared with its position disclosed in the audited accounts in the annual report of the Company for the year ended 31 December 2023) in the event that the Share Repurchase Mandate was to be exercised in full at any time during the proposed repurchase period. However, the Directors do not propose to exercise the Share Repurchase Mandate to such extent, as would, in the circumstances, have a material adverse effect on the working capital requirements or the gearing levels of the Company, which in the opinion of the Directors are from time to time appropriate for the Company. In the event the Company conducts a repurchase of Shares, the Company may cancel such repurchased Shares and/or hold them as treasury shares subject to, for example, market conditions and its capital management needs at the relevant time of the repurchases (the Company may use general mandate to allot, issue and deal with additional shares (including any sale or transfer of shares out of treasury that are held as treasury shares) after the relevant Listing Rules amendments have come into effect and upon fulfilment of relevant compliance obligations*). All Shares held as treasury shares retain their listing status.

* *The amended Listing Rules provisions will take effect on 11 June 2024. Under the amended Listing Rules, a listed issuer may use the general mandate approved by its shareholders to allot, issue and deal with additional shares (including any sale or transfer of shares out of treasury that are held as treasury shares).*

5. SHARE PRICES

The highest and lowest prices at which the Shares have been traded on the Stock Exchange for the 12 calendar months ended the Latest Practicable Date were as follows:

Month	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
2023		
April	49.40	33.15
May	38.10	28.40
June	37.50	32.80
July	36.85	31.25
August	38.10	33.05
September	38.10	33.20
October	34.75	29.20
November	37.35	31.70
December	36.35	30.90
2024		
January	36.25	31.25
February	37.05	28.75
March	45.50	35.05
April (<i>up to the Latest Practicable Date</i>)	47.75	41.45

6. GENERAL

To the best of their knowledge and having made all reasonable enquiries, none of the Directors nor any of their close associates (as defined in the Listing Rules) have any present intention to sell any Shares to the Company in the event that the grant of the Share Repurchase Mandate is approved by the Shareholders.

The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any Shares to the Company, or that they have undertaken not to sell any Shares held by them to the Company in the event that the grant of the Share Repurchase Mandate is approved by the Shareholders.

The Directors will exercise the power of the Company to repurchase Shares pursuant to the Share Repurchase Mandate in accordance with the Listing Rules and the applicable laws of the Cayman Islands.

The Company has confirmed that neither this explanatory statement nor the proposed Share Repurchase Mandate has any unusual features.

7. TAKEOVERS CODE

If as a result of a repurchase of Shares pursuant to the Share Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rules 26 of the Takeovers Code.

To the best knowledge of the Company, as at the Latest Practicable Date, Mr. Yan Jianya was deemed to be interested in 589,350,972 Shares, representing approximately 59.23% of the issued shares of the Company. Juzi Holding Co., Ltd., Refulgence Holding Limited and Trident Trust Company (B.V.I.) Limited were deemed to control of exercise of 581,104,935 Shares, representing approximately 58.40% of the issued shares of the Company. In the event that the Directors fully exercise the power to repurchase Shares pursuant to the proposed Share Repurchase Mandate, the shareholdings of Dr. Fan Daidi and Mr. Yan Jianya in the Company would be increased to approximately 65.81% of the issued shares of the Company, and the shareholdings of Juzi Holding Co., Ltd., Refulgence Holding Limited and Trident Trust Company (B.V.I.) Limited in the Company would be increased to approximately 64.89% of the issued shares of the Company.

The Directors consider that the increases in shareholdings would not give rise to an obligation to make a mandatory offer under Rule 26 of the Takeovers Code.

The Directors do not propose to exercise the Share Repurchase Mandate to such an extent as would, in the circumstances, give rise to an obligation to make a mandatory offer in accordance with Rule 26 of the Takeovers Code and/or result in the total number of Shares held by the public falling below the prescribed minimum percentage required by the Stock Exchange.

8. SHARE REPURCHASE MADE BY THE COMPANY

During the six months prior to the Latest Practicable Date, the Company had not repurchased any of the Shares (whether on the Stock Exchange or otherwise).

Article	Provisions of the Memorandum and Articles of Association	Proposed Amendments to the Memorandum and Articles of Association
Amended and Restated Articles of Association		
1.1 Interpretation of "Corporate Communication"	-	<p>The interpretation of "Corporate Communication" is proposed to be inserted in Article 1.1:</p> <p><u>"Corporate Communication" has the same meaning as in the Listing Rules.</u></p>
41.1	<p>The Company shall at every annual general meeting by Ordinary Resolution appoint an Auditor of the Company who shall hold office until the next annual general meeting of the Company. The Company may by Ordinary Resolution remove an Auditor before the expiration of such Auditor's term of office. No person may be appointed as an Auditor unless such person is independent of the Company. The remuneration of the Auditors shall be fixed by the Company at the annual general meeting at which they are appointed by Ordinary Resolution.</p>	<p>Article 41.1 is proposed to be amended as:</p> <p>The Company shall at every annual general meeting by Ordinary Resolution appoint an Auditor of the Company who shall hold office until the next annual general meeting of the Company. The Company may by Ordinary Resolution remove an Auditor before the expiration of such Auditor's term of office. No person may be appointed as an Auditor unless such person is independent of the Company. The remuneration of the Auditors shall be fixed by the Company at the annual general meeting at which they are appointed by Ordinary Resolution, <u>or in the manner specified in such resolution.</u></p>
41.2	-	<p>The following is proposed to be inserted as Article 41.2:</p> <p><u>If the office of Auditor becomes vacant by the resignation or death of the Auditor, or by the Auditor becoming incapable of acting by reason of illness or other disability, the Directors may fill the casual vacancy in the office of Auditor. The Auditor so appointed shall hold office until the next annual general meeting of the Company.</u></p>

Article	Provisions of the Memorandum and Articles of Association	Proposed Amendments to the Memorandum and Articles of Association
41.3	The Auditors of the Company shall have a right of access at all times to the books and accounts and vouchers of the Company and shall be entitled to require from the Directors and officers of the Company such information and explanation as may be necessary for the performance of the duties of the Auditors.	Article 41.2 in the Articles of Association is proposed to be re-numbered as Article 41.3. The content remains unchanged.
41.4	The Auditors shall audit the profit and loss account and balance sheet of the Company in each year and shall prepare a report thereon to be annexed thereto. Such report shall be laid before the Company at its annual general meeting in each year and shall be open to inspection by any Member. The Auditors shall at the next annual general meeting following their appointment and at any other time during their term of office, upon request of the Directors or any general meeting of the Members, make a report on the accounts of the Company during their term of office.	Article 41.3 in the Articles of Association is proposed to be re-numbered as Article 41.4. The content remains unchanged.

Article	Provisions of the Memorandum and Articles of Association	Proposed Amendments to the Memorandum and Articles of Association
42.1	<p>Except as otherwise provided in the Articles, any notice or document may be served by the Company on any Member either personally or by sending it through the post in a prepaid letter addressed to such Member at their registered address as appearing in the Register of Members or, to the extent permitted by the Listing Rules and all applicable laws and regulations, by Electronic Means by transmitting it to any electronic number or address or website supplied by the Member to the Company, or by placing it on the Company's Website or the Exchange's website provided that the Company has obtained either (a) the Member's prior express positive confirmation in writing; or (b) the Member's deemed consent in the manner specified in the Listing Rules to receive or otherwise have made available to such Member notices and documents to be given or issued to them by the Company by such Electronic Means, or (in the case of notice) by advertisement published in the manner prescribed in the Listing Rules. In the case of joint holders of a Share, all notices shall be given to that holder for the time being whose name stands first in the Register of Members and notice so given shall be sufficient notice to all the joint holders.</p>	<p>Article 42.1 is proposed to be amended as:</p> <p>Except as otherwise provided in the Articles, any notice or document, <u>including any Corporate Communication</u>, may be served by the Company on any Member <u>in any of the following manner to the extent permitted by, and in compliance with the requirements of, the Listing Rules:</u></p> <p>(a) <u>personally by leaving it at the registered address of such Member as appearing in the Register of Members;</u></p> <p>(b) <u>by sending it through the post in a prepaid letter addressed to such Member at their registered address as appearing in the Register of Members (which shall be sent by airmail where the notice or document is posted from one country to another);</u></p> <p>(c) <u>by Electronic Means by transmitting it to any electronic number or address or website supplied by the Member to the Company;</u></p> <p>(d) <u>by placing it on the Company's Website and the Exchange's website; or</u></p> <p>(e) <u>(in the case of notice) by advertisement published in the manner prescribed in the Listing Rules.</u></p> <p>In the case of joint holders of a Share, all notices shall be given to that holder for the time being whose name stands first in the Register of Members and notice so given shall be sufficient notice to all the joint holders.</p>

Article	Provisions of the Memorandum and Articles of Association	Proposed Amendments to the Memorandum and Articles of Association
42.2	<p>Any notice or document:</p> <p>(a) sent by post shall be deemed to have been served on the day following that on which the envelope containing the same, properly prepaid and addressed, is put into a post office; and in proving such service it shall be sufficient to prove that the envelope containing the notice or document was properly prepaid, addressed and put into such post office and a certificate in writing signed by the Secretary or other person appointed by the Directors that the envelope containing the notice or document was so addressed and put into such post office shall be conclusive evidence thereof;</p> <p>(b) delivered personally or left at a registered address otherwise than by post shall be deemed to have been served on the day it was so delivered or left;</p> <p>(c) served by advertisement shall be deemed to have been served on the day of issue of the official publication and/or newspapers in which the advertisement is published (or on the last day of issue if the publication and/or newspapers are published on different dates);</p>	<p>Article 42.2 is proposed to be amended as:</p> <p>Any notice or document, <u>including any Corporate Communication</u>:</p> <p>(a) <u>delivered personally or left at a registered address otherwise than by post shall be deemed to have been served on the day it was so delivered or left;</u></p> <p>(b) sent by post shall be deemed to have been served on the day following that on which the envelope containing the same, properly prepaid and addressed, is put into a post office; and in proving such service it shall be sufficient to prove that the envelope containing the notice or document was properly prepaid, addressed and put into such post office and a certificate in writing signed by the Secretary or other person appointed by the Directors that the envelope containing the notice or document was so addressed and put into such post office shall be conclusive evidence thereof;</p> <p>(c) given by Electronic Means as provided in the Articles shall be deemed to have been served and delivered on the day following that on which it is successfully transmitted or at such later time as may be prescribed by the Listing Rules or any applicable laws or regulations, and it shall not be necessary for the receipt of the electronic transmission to be acknowledged by the recipient;</p>

Article	Provisions of the Memorandum and Articles of Association	Proposed Amendments to the Memorandum and Articles of Association
	<p>(d) given by Electronic Means as provided in the Articles shall be deemed to have been served and delivered on the day following that on which it is successfully transmitted or at such later time as may be prescribed by the Listing Rules or any applicable laws or regulations, and it shall not be necessary for the receipt of the electronic transmission to be acknowledged by the recipient; and</p> <p>(e) served by being placed on the Company's Website <u>or</u> the Exchange's website shall be deemed to be served at such time as may be prescribed by the Listing Rules.</p>	<p>(d) served by being placed on the Company's Website <u>and</u> the Exchange's website shall be deemed to be served at such time as may be prescribed by the Listing Rules; <u>and</u></p> <p>(e) <u>served by advertisement shall be deemed to have been served on the day of issue of the official publication and/or newspapers in which the advertisement is published (or on the last day of issue if the publication and/or newspapers are published on different dates).</u></p>



GIANT BIOGENE HOLDING CO., LTD

巨子生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

NOTICE IS HEREBY GIVEN that an annual general meeting of Giant Biogene Holding Co., Ltd (the “**Company**”) will be held at No. 1855, Shanglin Yuan 7th Road, Chang’an District, Xi’an, Shaanxi Province, the PRC on Thursday, 13 June 2024 at 1:30 p.m. for the following purposes:

ORDINARY RESOLUTIONS

1. To receive the audited consolidated financial statements, directors’ report and auditor’s report of the Company for the year ended 31 December 2023.
2.
 - (a) To re-elect Mr. Yan Jianya as an executive director;
 - (b) To re-elect Ms. Ye Juan as an executive director;
 - (c) To re-elect Ms. Zhang Huijuan as an executive director;
 - (d) To re-elect Ms. Yan Yubo as an executive director; and
 - (e) To authorize the board of directors to fix the respective directors’ remuneration.
3. To re-appoint Ernst & Young as the auditor of the Group and to authorize the board of directors to fix its remuneration.
4. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“THAT:

- (a) subject to the compliance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and paragraph (b) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company to exercise during the Relevant Period (as defined below) all the powers of the Company to repurchase the shares of the Company in accordance with all applicable laws, rules and regulations;

NOTICE OF ANNUAL GENERAL MEETING

(b) the total number of shares approved to be repurchased by the Company pursuant to the mandate in paragraph (a) above shall not exceed 10% of the total issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidations or subdivisions of the shares of the Company after the passing of this resolution); and

(c) for the purposes of this resolution:

“Relevant Period” means the period from the time of the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of the Company or other applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders at general meeting.”

5. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT:**

(a) subject to the compliance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and paragraph (b) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company to allot, issue and deal with additional shares in the share capital of the Company and to make or grant offers, agreements and options which would or might require the exercise of such powers under all applicable laws, rules and regulations during or after the Relevant Period (as defined below);

(b) the total number of shares allotted or agreed conditionally or unconditionally to be allotted by the directors pursuant to the mandate in paragraph (a) above, otherwise than pursuant to:

(i) a Rights Issue (as defined below);

(ii) the issue of shares upon the exercise of options granted under a share option scheme of the Company; and

NOTICE OF ANNUAL GENERAL MEETING

- (iii) any scrip dividend scheme or similar arrangement providing for the allotment in lieu of the whole or part of a dividend on the shares of the Company in accordance with the Articles of the Company;

shall not exceed 20% of the total issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidations or subdivisions of the shares of the Company after the passing of this resolution); and

- (c) for the purposes of this resolution:

“Relevant Period” means the period from the time of the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of the Company or other applicable laws to be held; and
- (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders at general meeting.

“Rights Issue” means an offer of shares open for a period fixed by the directors to the holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction or the requirements of any recognized regulatory body or any stock exchange).”

- 6. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT** conditional upon the passing of resolutions set out in items 4 and 5 of the notice convening this meeting (the “**Notice**”), the general mandate referred to in resolution set out in item 5 of the Notice be and is hereby extended by the addition to the total number of shares which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued by the directors pursuant to such general mandate of an amount representing the total number of shares may be repurchased by the Company pursuant to the mandate referred to in resolution set out in item 4 of the

NOTICE OF ANNUAL GENERAL MEETING

Notice, provided that such number of shares shall not exceed 10% of the total issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidations or subdivisions of the shares of the Company after the passing of this resolution).”

7. (a) To declare and distribute a final dividend of RMB0.44 per ordinary share for the year ended 31 December 2023 to the shareholders of the Company;
- (b) To declare and distribute a special dividend of RMB0.45 per ordinary share for the year ended 31 December 2023 to the shareholders of the Company.

SPECIAL RESOLUTION

8. To consider and, if thought fit, approve the following resolution as a special resolution:

“**THAT** the amended and restated memorandum and articles of association of the Company (the “**Amended and Restated Memorandum and Articles of Association**”), be and are hereby approved and adopted, a copy of which marked “A” has been produced to the meeting and initialed by the chairman of the meeting for identification, in substitution for and to the exclusion of the existing Memorandum and Articles of Association of the Company in immediate effect upon the conclusion of the meeting, and directors be and are authorized to do all acts necessary for implementing the adoption of the Amended and Restated Memorandum and Articles of Association.”

By order of the Board
Giant Biogene Holding Co., Ltd
Yan Jianya
Chairman of the Board

Xi’an, the PRC, 29 April 2024

As of the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive directors.

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the requirements under the Listing Rules.
2. Any shareholder of the Company entitled to attend and vote at the meeting is entitled to appoint one or more proxies to attend the meeting and vote on a poll on his/her behalf. A proxy need not be a member of the Company. If more than one proxy is so appointed, the form of proxy shall specify the number of shares in respect of which each such proxy is so appointed. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him/her.
3. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a notorially certified copy of that power of attorney or authority, must be deposited at the Company’s Hong Kong Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours before the time appointed for holding the meeting (as the case may be) (for annual general meeting, i.e. not later than 1:30 p.m. on Tuesday, 11 June 2024 (Hong Kong time)) or any adjournment thereof. Completion and return of the form of proxy shall not preclude a member of the Company from attending and voting in person at the meeting and, in such event, the form of proxy previously submitted shall be deemed to be revoked.
4. For determining the entitlement to attend and vote at the meeting, the register of members of the Company will be closed from Friday, 7 June 2024 to Thursday, 13 June 2024, both days inclusive, during which period no transfer of shares will be registered. In order to qualify for attending and voting at annual general meeting, unregistered shareholders of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s Hong Kong Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Thursday, 6 June 2024.
5. The record date for determining the entitlement to the proposed final dividends and the special dividends will be 21 June 2024. To determine the entitlement of shareholders to the proposed final dividends and the special dividends, the register of the Company will be closed from 19 June 2024 to 21 June 2024, both days inclusive, during which period no transfer of shares of the Company will be registered. In order to be qualified for the proposed final dividends and the special dividends, all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s Hong Kong Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on 18 June 2024.
6. A circular containing further details concerning items 2 to 8 set out in the above notice will be dispatched to all shareholders together with the 2023 Annual Report of the Company.
7. References to time and dates in this notice are to Hong Kong time and dates.